Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models

Drug Metabolism Reviews

Volumn 43, Issue 1, 2011, Pages 27-40

  Jiang, Xi Ling ^a   Gonzalez, Frank J ^b   Yu, Ai Ming ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cancer; drug interaction; drug metabolism; humanized; knockout; pharmacokinetics; toxicity; Transgenic

Indexed keywords

4 HYDROXYDEBRISOQUINE; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; BENZODIAZEPINE; CAFFEINE; COTININE; COUMARIN; CYCLOSPORIN A; DEBRISOQUINE; DESIPRAMINE; DEXAMETHASONE; DIGOXIN; DOCETAXEL; DRUG METABOLIZING ENZYME; IMMUNOMODULATING AGENT; IVERMECTIN; KETOCONAZOLE; LOPERAMIDE; MIDAZOLAM; MITOXANTRONE; NICOTINE; ONDANSETRON; PARACETAMOL; PROTON PUMP INHIBITOR; STEROID; THEOPHYLLINE; TRIAZOLAM; UNINDEXED DRUG; VINBLASTINE; XENOBIOTIC AGENT;

AREA UNDER THE CURVE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HYDROXYLATION; DRUG INHIBITION; DRUG METABOLISM; DRUG TRANSPORT; DRUG UPTAKE; ENZYME METABOLISM; ENZYME SUBSTRATE; EXPERIMENTAL MODEL; FIRST PASS EFFECT; GENE EXPRESSION; HORMONAL REGULATION; HUMAN; IN VIVO STUDY; KNOCKOUT MOUSE; MOLECULAR CLONING; NONHUMAN; PHARMACOGENETICS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SEX DIFFERENCE; TRANSGENIC MOUSE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DISCOVERY; HUMANS; MEMBRANE TRANSPORT PROTEINS; METABOLIC DETOXICATION, DRUG; MICE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; XENOBIOTICS;

EID: 79951893032     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2010.512294     Document Type: Review

References (139)

1. Belinsky, M. G., Dawson, P. A., Shchaveleva, I., Bain, L. J., Wang, R., Ling, V., et al. (2005). Analysis of the in vivo functions of Mrp3. Mol Pharmacol 68:160-168. (Pubitemid 41002955)
2. Bogaards, J. J., Bertrand, M., Jackson, P., Oudshoorn, M. J., Weaver, R. J., van Bladeren, P. J., et al. (2000). Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey, and man. Xenobiotica 30:1131-1152. (Pubitemid 32368013)
3. Bonzo, J. A., Belanger, A., Tukey, R. H. (2007). The role of chrysin and the ah receptor in induction of the human UGT1A1 gene in vitro and in transgenic UGT1 mice. Hepatology 45:349-360. (Pubitemid 46374591)
4. Breedveld, P., Pluim, D., Cipriani, G., Wielinga, P., van Tellingen, O., Schinkel, A. H., et al. (2005). The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65:2577-2582. (Pubitemid 40490054)
5. Buters, J. T., Sakai, S., Richter, T., Pineau, T., Alexander, D. L., Savas, U., et al. (1999). Cytochrome P450 CYP1B1 determines susceptibility to 7,12-dimethylbenz[a]anthracene-induced lymphomas. Proc Natl Acad Sci USA 96:1977-1982. (Pubitemid 29117853)
6. Buters, J. T., Tang, B. K., Pineau, T., Gelboin, H. V., Kimura, S., Gonzalez, F. J. (1996). Role of CYP1A2 in cafeine pharmacoki-netics and metabolism: studies using mice defcient in CYP1A2. Pharmacogenetics 6:291-296. (Pubitemid 26288619)
7. Cai, H., Nguyen, N., Peterkin, V., Yang, Y. S., Hotz, K., La Placa, D. B., et al. (2010). A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation. Drug Metab Dispos 38:879-886.
8. Chen, C., Stock, J. L., Liu, X., Shi, J., Van Deusen, J. W., DiMattia, D. A., et al. (2008). Utility of a novel Oatp1b2 knockout mouse model for evaluating the role of Oatp1b2 in the hepatic uptake of model compounds. Drug Metab Dispos 36:1840-1845.
9. Chen, S., Beaton, D., Nguyen, N., Senekeo-Efenberger, K., Brace-Sinnokrak, E., Argikar, U., et al. (2005). Tissue-specifc, inducible, and hormonal control of the human UDP-glucuronosyltransferase-1 (UGT1) locus. J Biol Chem 280:37547-37557. (Pubitemid 41642363)
10. Cheung, C., Akiyama, T. E., Ward, J. M., Nicol, C. J., Feigenbaum, L., Vinson, C., et al. (2004). Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome prolifer-ator-activated receptor alpha. Cancer Res 64:3849-3854. (Pubitemid 38697295)
11. Cheung, C., Ma, X., Krausz, K. W., Kimura, S., Feigenbaum, L., Dalton, T. P., et al. (2005a). Diferential metabolism of 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2. Chem Res Toxicol 18:1471-1478. (Pubitemid 41361721)
12. Cheung, C., Yu, A. M., Chen, C. S., Krausz, K. W., Byrd, L. G., Feigenbaum, L., et al. (2006). Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice. J Pharmacol Exp Ter 316:1328-1334. (Pubitemid 43345309)
13. Cheung, C., Yu, A. M., Ward, J. M., Krausz, K. W., Akiyama, T. E., Feigenbaum, L., et al. (2005b). The cyp2e1-humanized transgenic mouse: role of cyp2e1 in acetaminophen hepatotoxicity. Drug Metab Dispos 33:449-457. (Pubitemid 40279947)
14. Chu, X. Y., Strauss, J. R., Mariano, M. A., Li, J., Newton, D. J., Cai, X., et al. (2006). Characterization of mice lacking the multi-drug resistance protein, MRP2 (ABCC2). J Pharmacol Exp Ter 317:579-589.
15. Conklin, D. J., Haberzettl, P., Prough, R. A., Bhatnagar, A. (2009). Glutathione-S-transferase P protects against endothelial dysfunction induced by exposure to tobacco smoke. Am J Physiol Heart Circ Physiol 296:H1586-H1597.
16. Corchero, J., Granvil, C. P., Akiyama, T. E., Hayhurst, G. P., Pimprale, S., Feigenbaum, L., et al. (2001). The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol Pharmacol 60:1260-1267. (Pubitemid 33144897)
17. Dai, G., Chou, N., He, L., Gyamf, M. A., Mendy, A. J., Slitt, A. L., et al. (2005). Retinoid X receptor alpha regulates the expression of glutathione S-transferase genes and modulates acetami-nophen-glutathione conjugation in mouse liver. Mol Pharmacol 68:1590-1596. (Pubitemid 41654343)
18. Dai, G., Wan, Y. J. (2005). Animal models of xenobiotic receptors. Curr Drug Metab 6:341-355. (Pubitemid 41086767)
19. Dalton, T. P., Dieter, M. Z., Matlib, R. S., Childs, N. L., Shertzer, H. G., Genter, M. B., et al. (2000). Targeted knockout of Cyp1a1 gene does not alter hepatic constitutive expression of other genes in the mouse [Ah] battery. Biochem Biophys Res Commun 267:184-189. (Pubitemid 30072528)
20. Derkenne, S., Curran, C. P., Shertzer, H. G., Dalton, T. P., Dragin, N., Nebert, D. W. (2005). Teophylline pharmacokinetics comparison of Cyp1a1(-/-) and Cyp1a2(-/-) knockout mice, humanized hCYP1A1-1A2 knock-in mice lacking either the mouse Cyp1a1 or Cyp1a2 gene, and Cyp1(+/+) wild-type mice. Pharmacogenet Genomics 15:503-511.
21. Dragin, N., Uno, S., Wang, B., Dalton, T. P., Nebert, D. W. (2007). Generation of "humanized" hCYP1A1-1A2-Cyp1a1/1a2(-/-) mouse line. Biochem Biophys Res Commun 359:635-642.
22. Eraly, S. A., Vallon, V., Vaughn, D. A., Gangoiti, J. A., Richter, K., Nagle, M., et al. (2006). Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice. J Biol Chem 281:5072-5083. (Pubitemid 43847773)
23. Fang, C., Behr, M., Xie, F., Lu, S., Doret, M., Luo, H., et al. (2008a). Mechanism of chloroform-induced renal toxicity: non-involvement of hepatic cytochrome P450-dependent metabolism. Toxicol Appl Pharmacol 227:48-55. (Pubitemid 351179853)
24. Fang, C., Gu, J., Xie, F., Behr, M., Yang, W., Abel, E. D., et al. (2008b). Deletion of the NADPH-cytochrome P450 reductase gene in car-diomyocytes does not protect mice against doxorubicin-medi-ated acute cardiac toxicity. Drug Metab Dispos 36:1722-1728.
25. Felmlee, M. A., Lon, H. K., Gonzalez, F. J., Yu, A. M. (2008). Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double trans-genic humanized mice. Drug Metab Dispos 36:435-441. (Pubitemid 351185758)
26. Fernandez-Salguero, P., Pineau, T., Hilbert, D. M., McPhail, T., Lee, S. S., Kimura, S., et al. (1995). Immune system impairment and hepatic fbrosis in mice lacking the dioxin-binding Ah receptor. Science 268:722-726.
27. Finn, R. D., McLaren, A. W., Carrie, D., Henderson, C. J., Wolf, C. R. (2007). Conditional deletion of cytochrome P450 oxi-doreductase in the liver and gastrointestinal tract: a new model for studying the functions of the P450 system. J Pharmacol Exp Ter 322:40-47. (Pubitemid 46956358)
28. Foreman, J. E., Chang, S. C., Ehresman, D. J., Butenhof, J. L., Anderson, C. R., Palkar, P. S., et al. (2009). Diferential hepatic efects of perfuorobutyrate mediated by mouse and human PPAR-alpha. Toxicol Sci 110:204-211.
29. Fujiwara, R., Nguyen, N., Chen, S., Tukey, R. H. (2010). Developmental hyperbilirubinemia and CNS toxicity in mice humanized with the UDP glucuronosyltransferase 1 (UGT1) locus. Proc Natl Acad Sci USA 107:5024-5029.
30. Gomez, A., Ingelman-Sundberg, M. (2009). Pharmacoepigenetics: its role in interindividual diferences in drug response. Clin Pharmacol Ter 85:426-430.
31. Gonzalez, F. J. (2003). Role of gene knockout and transgenic mice in the study of xenobiotic metabolism. Drug Metab Rev 35: 319-335. (Pubitemid 38018110)
32. Gonzalez, F. J., Kimura, S. (2003). Study of P450 function using gene knockout and transgenic mice. Arch Biochem Biophys 409:153-158. (Pubitemid 36042911)
33. Gonzalez, F. J., Peters, J. M., Cattley, R. C. (1998). Mechanism of action of the nongenotoxic peroxisome proliferators: role of the per-oxisome proliferator-activator receptor alpha. J Natl Cancer Inst 90:1702-1709. (Pubitemid 28539089)
34. Gonzalez, F. J., Yu, A. M. (2006). Cytochrome P450 and xenobi-otic receptor humanized mice. Annu Rev Pharmacol Toxicol 46:41-64. (Pubitemid 43271183)
35. Granvil, C. P., Yu, A. M., Elizondo, G., Akiyama, T. E., Cheung, C., Feigenbaum, L., et al. (2003). Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. Drug Metab Dispos 31:548-558. (Pubitemid 36444163)
36. Gu, J., Chen, C. S., Wei, Y., Fang, C., Xie, F., Kannan, K., et al. (2007). A mouse model with liver-specifc deletion and global suppression of the NADPH-cytochrome P450 reductase gene: characterization and utility for in vivo studies of cyclophosphamide disposition. J Pharmacol Exp Ter 321:9-17. (Pubitemid 46456993)
37. Gu, J., Weng, Y., Zhang, Q. Y., Cui, H., Behr, M., Wu, L., et al. (2003). Liver-specifc deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J Biol Chem 278:25895-25901. (Pubitemid 36835351)
38. Henderson, C. J., Otto, D. M., Carrie, D., Magnuson, M. A., McLaren, A. W., Rosewell, I., et al. (2003a). Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J Biol Chem 278:13480-13486. (Pubitemid 36800122)
39. Henderson, C. J., Otto, D. M., McLaren, A. W., Carrie, D., Wolf, C. R. (2003b). Knockout mice in xenobiotic metabolism. Drug Metab Rev 35:385-392. (Pubitemid 38018113)
40. Henderson, C. J., Pass, G. J., Wolf, C. R. (2006). The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity. Toxicol Lett 162:111-117. (Pubitemid 43243162)
41. Henderson, C. J., Smith, A. G., Ure, J., Brown, K., Bacon, E. J., Wolf, C. R. (1998). Increased skin tumorigenesis in mice lacking Pi class glu-tathione S-transferases. Proc Natl Acad Sci USA 95:5275-5280.
42. Henderson, C. J., Wolf, C. R. (2003). Transgenic analysis of human drug-metabolizing enzymes: preclinical drug development and toxicology. Mol Interv 3:331-343.
43. Henderson, C. J., Wolf, C. R., Kitteringham, N., Powell, H., Otto, D., Park, B. K. (2000). Increased resistance to acetaminophen hepa-totoxicity in mice lacking glutathione S-transferase Pi. Proc Natl Acad Sci USA 97:12741-12745.
44. Huang, W., Zhang, J., Moore, D. D. (2004). A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor, CAR. J Clin Invest 113:137-143. (Pubitemid 38541640)
45. Imaoka, T., Kusuhara, H., Adachi, M., Schuetz, J. D., Takeuchi, K., Sugiyama, Y. (2007). Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol 71:619-627. (Pubitemid 46147926)
46. Ingelman-Sundberg, M., Sim, S. C., Gomez, A., Rodriguez-Antona, C. (2007). Infuence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic, and clinical aspects. Pharmacol Ter 116:496-526. (Pubitemid 350116943)
47. Jiang, X. L., Shen, H. W., Yu, A. M. (2009). Pinoline may be used as a probe for CYP2D6 activity. Drug Metab Dispos 37:443-446.
48. Jiang, Z., Dalton, T. P., Jin, L., Wang, B., Tsuneoka, Y., Shertzer, H. G., et al. (2005). Toward the evaluation of function in genetic variability: characterizing human SNP frequencies and establishing BAC-transgenic mice carrying the human CYP1A1-CYP1A2 locus. Hum Mutat 25:196-206. (Pubitemid 40216616)
49. Jonker, J. W., Buitelaar, M., Wagenaar, E., Van Der Valk, M. A., Schefer, G. L., Scheper, R. J., et al. (2002). The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 99:15649-15654. (Pubitemid 35403986)
50. Jonker, J. W., Merino, G., Musters, S., van Herwaarden, A. E., Bolscher, E., Wagenaar, E., et al. (2005). The breast cancer resistance protein, BCRP (ABCG2), concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 11:127-129. (Pubitemid 40321346)
51. Jonker, J. W., Wagenaar, E., Mol, C. A., Buitelaar, M., Koepsell, H., Smit, J. W., et al. (2001). Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol 21:5471-5477. (Pubitemid 32702451)
52. Jonker, J. W., Wagenaar, E., Van Eijl, S., Schinkel, A. H. (2003). Defciency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol 23:7902-7908. (Pubitemid 37271485)
53. Kastner, P., Grondona, J. M., Mark, M., Gansmuller, A., LeMeur, M., Decimo, D., et al. (1994). Genetic analysis of RXR alpha developmental function: convergence of RXR and RAR signaling pathways in heart and eye morphogenesis. Cell 78:987-1003.
54. Kotegawa, T., Laurijssens B. E., Von Moltke, L. L., Cotreau, M. M., Perlof, M. D., Venkatakrishnan, K., et al. (2002). In vitro, pharma-cokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J Pharmacol Exp Ter 302:1228-1237. (Pubitemid 34920247)
55. Lagas, J. S., Vlaming, M. L., Schinkel, A. H. (2009). Pharmacokinetic assessment of multiple ATP-binding cassette transporters: the power of combination knockout mice. Mol Interv 9:136-145.
56. Lee, S. S., Buters, J. T., Pineau, T., Fernandez-Salguero, P., Gonzalez, F. J. (1996). Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 271:12063-12067. (Pubitemid 26157285)
57. Lee, S. S., Pineau, T., Drago, J., Lee, E. J., Owens, J. W., Kroetz, D. L., et al. (1995). Targeted disruption of the alpha isoform of the per-oxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic efects of peroxisome prolifera-tors. Mol Cell Biol 15:3012-3022.
58. Leggas, M., Adachi, M., Schefer, G. L., Sun, D., Wielinga, P., Du, G., et al. (2004). Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 24:7612-7621. (Pubitemid 39121487)
59. Li, Y., Cui, Y., Hart, S. N., Klaassen, C. D., Zhong, X. B. (2009). Dynamic patterns of histone methylation are associated with ontogenic expression of the Cyp3a genes during mouse liver maturation. Mol Pharmacol 75:1171-1179.
60. Liang, H. C., Li, H., McKinnon, R. A., Dufy, J. J., Potter, S. S., Puga, A., et al. (1996). Cyp1a2(-/-) null mutant mice develop normally but show defcient drug metabolism. Proc Natl Acad Sci USA 93:1671-1676. (Pubitemid 26075183)
61. Liggett, S. B. (2004). Genetically modifed mouse models for pharma-cogenomic research. Nat Rev Genet 5:657-663. (Pubitemid 39150122)
62. Lofgren, S., Baldwin, R. M., Carleros, M., Terelius, Y., Fransson-Steen, R., Mwinyi, J., et al. (2009). Regulation of human CYP2C18 and CYP2C19 in transgenic mice: infuence of castration, testosterone, and growth hormone. Drug Metab Dispos 37:1505-1512.
63. Lofgren, S., Baldwin, R. M., Hiratsuka, M., Lindqvist, A., Carlberg, A., Sim, S. C., et al. (2008). Generation of mice trans-genic for human CYP2C18 and CYP2C19: characterization of the sexually dimorphic gene and enzyme expression. Drug Metab Dispos 36:955-962. (Pubitemid 351574895)
64. Lorico, A., Rappa, G., Finch, R. A., Yang, D., Flavell, R. A., Sartorelli, A. C. (1997). Disruption of the murine MRP (multi-drug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Res 57:5238-5242. (Pubitemid 27516355)
65. Lu, H., Choudhuri, S., Ogura, K., Csanaky, I. L., Lei, X., Cheng, X., et al. (2008). Characterization of organic anion transporting polypep-tide 1b2-null mice: essential role in hepatic uptake/toxicity of phalloidin and microcystin-LR. Toxicol Sci 103:35-45. (Pubitemid 351524475)
66. Ma, X., Shah, Y., Cheung, C., Guo, G. L., Feigenbaum, L., Krausz, K. W., et al. (2007). The Pregnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cyto-chromes P450 3A. Drug Metab Dispos 35:194-200. (Pubitemid 46148730)
67. Manautou, J. E., de Waart, D. R., Kunne, C., Zelcer, N., Goedken, M., Borst, P., et al. (2005). Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene. Hepatology 42:1091-1098. (Pubitemid 43112676)
68. Manis, J. P. (2007). Knock out, knock in, knock down-genetically manipulated mice and the Nobel Prize. NEJM 357:2426-2429. (Pubitemid 350272781)
69. Merino, G., Alvarez, A. I., Pulido, M. M., Molina, A. J., Schinkel, A. H., Prieto, J. G. (2006). Breast cancer resistance protein (BCRP/ABCG2) transports fuoroquinolone antibiotics and afects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos 34:690-695.
70. Merino, G., Jonker, J. W., Wagenaar, E., van Herwaarden, A. E., Schinkel, A. H. (2005). The breast cancer resistance protein (BCRP/ABCG2) afects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic, nitrofurantoin. Mol Pharmacol 67:1758-1764. (Pubitemid 40594177)
71. Mimura, J., Yamashita, K., Nakamura, K., Morita, M., Takagi, T. N., Nakao, K., et al. (1997). Loss of teratogenic response to 2,3,7,8- tetrachlorodibenzo-p-dioxin (TCDD) in mice lacking the Ah (dioxin) receptor. Genes Cells 2:645-654. (Pubitemid 127688610)
72. Moriguchi, T., Motohashi, H., Hosoya, T., Nakajima, O., Takahashi, S., Ohsako, S., et al. (2003). Distinct response to dioxin in an aryl-hydrocarbon receptor (AHR)-humanized mouse. Proc Natl Acad Sci USA 100:5652-5657. (Pubitemid 36576863)
73. Morimura, K., Cheung, C., Ward, J. M., Reddy, J. K., Gonzalez, F. J. (2006). Diferential susceptibility of mice humanized for peroxi-some proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis. Carcinogenesis 27:1074-1080.
74. Muruganandan, S., Sinal, C. J. (2008). Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism. Clin Pharmacol Ter 83:818-828. (Pubitemid 351704925)
75. Mutch, D. M., Crespy, V., Clough, J., Henderson, C. J., Lariani, S., Mansourian, R., et al. (2006). Hepatic cytochrome P450 reductase-null mice show reduced transcriptional response to quercetin and reveal physiological homeostasis between jejunum and liver. Am J Physiol Gastrointest Liver Physiol 291:G63-G72. (Pubitemid 44024662)
76. Nguyen, N., Bonzo, J. A., Chen, S., Chouinard, S., Kelner, M. J., Hardiman, G., et al. (2008). Disruption of the ugt1 locus in mice resembles human Crigler-Najjar type I disease. J Biol Chem 283:7901-7911.
77. Otto, D. M., Henderson, C. J., Carrie, D., Davey, M., Gundersen, T. E., Blomhof, R., et al. (2003). Identifcation of novel roles of the cytochrome p450 system in early embryogenesis: efects on vasculogenesis and retinoic acid homeostasis. Mol Cell Biol 23:6103-6116. (Pubitemid 37013089)
78. Ou, Z., Huang, M., Zhao, L., Xie, W. (2010). Use of transgenic mice in UDP-glucuronosyltransferase (UGT) studies. Drug Metab Rev 42:119-127.
79. Pan, Y. Z., Gao, W., Yu, A. M. (2009). MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 37:2112-2117.
80. Pass, G. J., Carrie, D., Boylan, M., Lorimore, S., Wright, E., Houston, B., et al. (2005). Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse. Cancer Res 65:4211-4217. (Pubitemid 40775659)
81. Pineau, T., Fernandez-Salguero, P., Lee, S. S., McPhail, T., Ward, J. M., Gonzalez, F. J. (1995). Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450 1A2. Proc Natl Acad Sci USA 92:5134-5138.
82. Qian, Y. M., Sun, X. J., Tong, M. H., Li, X. P., Richa, J., Song, W. C. (2001). Targeted disruption of the mouse estrogen sulfotransferase gene reveals a role of estrogen metabolism in intracrine and paracrine estrogen regulation. Endocrinology 142:5342-5350. (Pubitemid 33131967)
83. Rao, A., Haywood, J., Craddock, A. L., Belinsky, M. G., Kruh, G. D., Dawson, P. A. (2008). The organic solute transporter alpha-beta, Ostalpha-Ostbeta, is essential for intestinal bile acid transport and homeostasis. Proc Natl Acad Sci USA 105:3891-3896. (Pubitemid 351723495)
84. Rubio-Aliaga, I., Frey, I., Boll, M., Groneberg, D. A., Eichinger, H. M., Balling, R., et al. (2003). Targeted disruption of the peptide transporter Pept2 gene in mice defnes its physiological role in the kidney. Mol Cell Biol 23:3247-3252. (Pubitemid 36459237)
85. Saini, S. P., Sonoda, J., Xu, L., Toma, D., Uppal, H., Mu, Y., et al. (2004). A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxifcation. Mol Pharmacol 65:292-300. (Pubitemid 38134256)
86. Schinkel, A. H., Mayer, U., Wagenaar, E., Mol, C. A., van Deemter, L., Smit, J. J., et al. (1997). Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94:4028-4033. (Pubitemid 27180493)
87. Schinkel, A. H., Smit, J. J., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., et al. (1994). Disruption of the mouse mdr1a P-glycoprotein gene leads to a defciency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502. (Pubitemid 24153990)
88. Schinkel, A. H., Wagenaar, E., Mol, C. A., van Deemter, L. (1996). P-glycoprotein in the blood-brain barrier of mice infuences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524. (Pubitemid 26187339)
89. Schinkel, A. H., Wagenaar, E., van Deemter, L., Mol, C. A., Borst, P. (1995). Absence of the mdr1a P-glycoprotein in mice afects tissue distribution and pharmacokinetics of dexamethasone, dig-oxin, and cyclosporin A. J Clin Invest 96:1698-1705.
90. Schmidt, J. V., Su, G. H., Reddy, J. K., Simon, M. C., Bradfeld, CA. (1996). Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proc Natl Acad Sci USA 93:6731-6736. (Pubitemid 26230378)
91. Senekeo-Efenberger, K., Chen, S., Brace-Sinnokrak, E., Bonzo, J. A., Yueh, M. F., Argikar, U., et al. (2007). Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY-14643) and implications on drug metabolism through peroxisome proliferator-activated receptor alpha activation. Drug Metab Dispos 35:419-427. (Pubitemid 46333905)
92. Shen, A. L., O'Leary, K. A., Kasper, C. B. (2002). Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase. J Biol Chem 277:6536-6541. (Pubitemid 34968452)
93. Shen, H., Ocheltree, S. M., Hu, Y., Keep, R. F., Smith, D. E. (2007). Impact of genetic knockout of PEPT2 on cefadroxil pharmacoki-netics, renal tubular reabsorption, and brain penetration in mice. Drug Metab Dispos 35:1209-1216. (Pubitemid 46956444)
94. Shen, H., Smith, D. E., Keep, R. F., Xiang, J., Brosius, F. C., 3rd. (2003). Targeted disruption of the PEPT2 gene markedly reduces dipep-tide uptake in choroid plexus. J Biol Chem 278:4786-4791. (Pubitemid 36800981)
95. Shen, H. W., Yu, AM. (2009). Diference in desipramine metabolic profle between wild-type and CYP2D6-humanized mice. Drug Metab Lett 3:234-241.
96. Staudinger, J. L., Goodwin, B., Jones, S. A., Hawkins-Brown, D., MacKenzie, K. I., LaTour, A., et al. (2001). The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA 98:3369-3374. (Pubitemid 32220852)
97. Sucov, H. M., Dyson, E., Gumeringer, C. L., Price, J., Chien, K. R., Evans, R. M. (1994). RXR alpha mutant mice establish a genetic basis for vitamin A signaling in heart morphogenesis. Genes Dev 8:1007-1018.
98. Sweet, D. H., Miller, D. S., Pritchard, J. B., Fujiwara, Y., Beier, D. R., Nigam, S. K. (2002). Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J Biol Chem 277:26934-26943. (Pubitemid 34951703)
99. Sykes, D., Sweet, D. H., Lowes, S., Nigam, S. K., Pritchard, J. B., Miller, DS. (2004). Organic anion transport in choroid plexus from wild-type and organic anion transporter 3 (Slc22a8)-null mice. Am J Physiol Renal Physiol 286:F972-F978. (Pubitemid 38508998)
100. Takenaka, K., Morgan, J. A., Schefer, G. L., Adachi, M., Stewart, C. F., Sun, D., et al. (2007). Substrate overlap between Mrp4 and Abcg2/ Bcrp afects purine analogue drug cytotoxicity and tissue distribution. Cancer Res 67:6965-6972. (Pubitemid 47105544)
101. Tong, M. H., Jiang, H., Liu, P., Lawson, J. A., Brass, L. F., Song, W. C. (2005). Spontaneous fetal loss caused by placental thrombosis in estrogen sulfotransferase-defcient mice. Nat Med 11:153-159. (Pubitemid 40321350)
102. Tsuda, M., Terada, T., Mizuno, T., Katsura, T., Shimakura, J., Inui, K. (2009). Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol 75:1280-1286.
103. Tsunoda, S. M., Velez, R. L., von Moltke, L. L., Greenblatt, D. J. (1999). Diferentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of keto-conazole. Clin Pharmacol Ter 66:461-471.
104. Uno, S., Dalton, T. P., Dragin, N., Curran, C. P., Derkenne, S., Miller, M. L., et al. (2006). Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total-body burden, and clearance rate. Mol Pharmacol 69:1103-1114.
105. Uno, S., Dalton, T. P., Sinclair, P. R., Gorman, N., Wang, B., Smith, A. G., et al. (2004). Cyp1a1(-/-) male mice: protection against high-dose TCDD-induced lethality and wasting syndrome, and resistance to intrahepatocyte lipid accumulation and uroporphyria. Toxicol Appl Pharmacol 196:410-421. (Pubitemid 38496464)
106. Van de Steeg, E., van der Kruijssen, C. M., Wagenaar, E., Burggraaf, J. E., Mesman, E., Kenworthy, K. E., et al. (2009). Methotrexate pharmacokinetics in transgenic mice with liver-specifc expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab Dispos 37:277-281.
107. Van Herwaarden, A. E., Jonker, J. W., Wagenaar, E., Brinkhuis, R. F., Schellens, J. H., Beijnen, J. H., et al. (2003). The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res 63:6447-6452. (Pubitemid 37255195)
108. Van Herwaarden, A. E., Smit, J. W., Sparidans, R. W., Wagenaar, E., van der Kruijssen, C. M., Schellens, J. H., et al. (2005). Midazolam and cyclosporin A metabolism in transgenic mice with liver-specifc expression of human CYP3A4. Drug Metab Dispos 33: 892-895. (Pubitemid 41002768)
109. Van Herwaarden, A. E., Wagenaar, E., van der Kruijssen, C. M., van Waterschoot, R. A., Smit, J. W., Song, J. Y., et al. (2007). Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 117:3583-3592. (Pubitemid 350097013)
110. Van Waterschoot, R. A., Rooswinkel, R. W., Sparidans, R. W., van Herwaarden, A. E., Beijnen, J. H., Schinkel, A. H. (2009). Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam. Drug Metab Dispos 37:2305-2313.
111. Van Waterschoot, R. A., van Herwaarden, A. E., Lagas, J. S., Sparidans, R. W., Wagenaar, E., van der Kruijssen, C. M., et al. (2008). Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Mol Pharmacol 73:1029-1036. (Pubitemid 351397908)
112. Vlaming, M. L., Mohrmann, K., Wagenaar, E., de Waart, D. R., Elferink, R. P., Lagas, J. S., et al. (2006). Carcinogen and antican-cer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ter 318:319-327.
113. Wan, Y. J., An, D., Cai, Y., Repa, J. J., Hung-Po Chen, T., Flores, M., et al. (2000). Hepatocyte-specifc mutation establishes retinoid X receptor alpha as a heterodimeric integrator of multiple physiological processes in the liver. Mol Cell Biol 20:4436-4444. (Pubitemid 30346638)
114. Wang, R., Lam, P., Liu, L., Forrest, D., Yousef, I. M., Mignault, D., et al. (2003). Severe cholestasis induced by cholic acid feeding in knockout mice of sister of P-glycoprotein. Hepatology 38:1489-1499. (Pubitemid 37466975)
115. Wang, R., Salem, M., Yousef, I. M., Tuchweber, B., Lam, P., Childs, S. J., et al. (2001). Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in nonprogressive but persistent intrahe-patic cholestasis. Proc Natl Acad Sci USA 98:2011-2016. (Pubitemid 32165614)
116. Wei, P., Zhang, J., Egan-Hafey, M., Liang, S., Moore, D. D. (2000). The nuclear receptor, CAR, mediates specifc xenobiotic induction of drug metabolism. Nature 407:920-923.
117. Weng, Y., Fang, C., Turesky, R. J., Behr, M., Kaminsky, L. S., Ding, X. (2007). Determination of the role of target tissue metabolism in lung carcinogenesis using conditional cytochrome P450 reduct-ase-null mice. Cancer Res 67:7825-7832. (Pubitemid 47281377)
118. Wijnholds, J., Evers, R., van Leusden, M. R., Mol, C. A., Zaman, G. J., Mayer, U., et al. (1997). Increased sensitivity to anticancer drugs and decreased infammatory response in mice lacking the multi-drug resistance-associated protein. Nat Med 3:1275-1279. (Pubitemid 27508831)
119. Wu, C., Jiang, X. L., Shen, H. W., Yu, A. M. (2009). Efects of CYP2D6 status on harmaline metabolism, pharmacokinetics, and phar-macodynamics, and a pharmacogenetics-based pharmacokinetic model. Biochem Pharmacol 78:617-624.
120. Wu, L., Gu, J., Cui, H., Zhang, Q. Y., Behr, M., Fang, C., et al. (2005). Transgenic mice with a hypomorphic NADPH-cytochrome P450 reductase gene: efects on development, reproduction, and microsomal cytochrome P450. J Pharmacol Exp Ter 312:35-43. (Pubitemid 40096450)
121. Wu, L., Gu, J., Weng, Y., Kluetzman, K., Swiatek, P., Behr, M., et al. (2003). Conditional knockout of the mouse NADPH-cytochrome p450 reductase gene. Genesis 36:177-181. (Pubitemid 37087689)
122. Wu, Y., Zhang, X., Bardag-Gorce, F., Robel, R. C., Aguilo, J., Chen, L., et al. (2004). Retinoid X receptor alpha regulates glutathione homeostasis and xenobiotic detoxifcation processes in mouse liver. Mol Pharmacol 65:550-557. (Pubitemid 38264022)
123. Xia, C. Q., Milton, M. N., Gan, L. S. (2007). Evaluation of drug-transporter interactions using in vitro and in vivo models. Curr Drug Metab 8:341-363. (Pubitemid 46780063)
124. Xie, W., Barwick, J. L., Downes, M., Blumberg, B., Simon, C. M., Nelson, M. C., et al. (2000). Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406:435-439. (Pubitemid 30625566)
125. Yu, A. M. (2007). Small interfering RNA in drug metabolism and transport. Curr Drug Metab 8:700-708.
126. Yu, A. M. (2009). Role of microRNAs in the regulation of drug metabolism and disposition. Exp Opin Drug Metab Toxicol 5:1513-1528.
127. Yu, A. M., Fukamachi, K., Krausz, K. W., Cheung, C., Gonzalez, F. J. (2005). Potential role for human cytochrome P450 3A4 in estra-diol homeostasis. Endocrinology 146:2911-2919. (Pubitemid 41002798)
128. Yu, A. M., Granvil, C. P., Haining, R. L., Krausz, K. W., Corchero, J., Kupfer, A., et al. (2003a). The relative contribution of monoam-ine oxidase and cytochrome p450 isozymes to the metabolic deamination of the trace amine, tryptamine. J Pharmacol Exp Ter 304:539-546. (Pubitemid 36152328)
129. Yu, A. M., Idle, J. R., Byrd, L. G., Krausz, K. W., Kupfer, A., et al. (2003b). Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 13: 173-181. (Pubitemid 36324247)
130. Yu, A. M., Idle, J. R., Gonzalez, F. J. (2004). Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev 36:243-277. (Pubitemid 38802489)
131. Yu, A. M., Idle, J. R., Herraiz, T., Kupfer, A., Gonzalez, F. J. (2003c). Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 13:307-319. (Pubitemid 36724524)
132. Zaher, H., Meyer Zu Schwabedissen, H. E., Tirona, R. G., Cox, M. L., Obert, L. A., Agrawal, N., et al. (2008). Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/ Slco1b2) signifcantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol 74: 320-329.
133. Zelcer, N., van de Wetering, K., de Waart, R., Schefer, G. L., Marschall, H. U., Wielinga, P. R., et al. (2006). Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J Hepatol 44:768-775.
134. Zhang, J., Huang, W., Chua, S. S., Wei, P., Moore, D. D. (2002). Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science 298:422-424. (Pubitemid 35176352)
135. Zhang, Q. Y., Fang, C., Zhang, J., Dunbar, D., Kaminsky, L., Ding, X. (2009). An intestinal epithelium-specifc cytochrome P450 (P450) reductase-knockout mouse model: direct evidence for a role of intestinal p450s in frst-pass clearance of oral nifedipine. Drug Metab Dispos 37:651-657.
136. Zhang, Q. Y., Gu, J., Su, T., Cui, H., Zhang, X., D'Agostino, J., et al. (2005). Generation and characterization of a transgenic mouse model with hepatic expression of human CYP2A6. Biochem Biophys Res Commun 338:318-324. (Pubitemid 41540573)
137. Zhou, S., Morris, J. J., Barnes, Y., Lan, L., Schuetz, J. D., Sorrentino, B. P. (2002). Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci USA 99:12339-12344.
138. Zhou, X., Zhuo, X., Xie, F., Kluetzman, K., Shu, Y. Z., Humphreys, W. G., et al. (2009). Role of CYP2A5 in the clearance of nicotine and cotinine: insights from studies on a Cyp2a5-null mouse model. J Pharmacol Exp Ter 332:578-587.
139. Zwart, R., Verhaagh, S., Buitelaar, M., Popp-Snijders, C., Barlow, D. P. (2001). Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-defcient mice. Mol Cell Biol 21:4188-4196. (Pubitemid 32565301)